凝固因子濃縮物:過去,現在,未来
1University of North Carolina School of Medicine and Harold R Roberts Comprehensive Hemophilia Diagnostic and Treatment Center, Chapel Hill, NC, USA. Nigel_Key@med.unc.edu
Lancet (London, England)
|August 7, 2007
まとめ
凝固因子濃縮剤は著しく改善され,血友病患者の病原体伝播リスクを低減しました. 将来の治療は,有効性を高め,免疫原性を減らすために,バイオエンジニアリングされたタンパク質に焦点を当てています.
科学分野:
- バイオテクノロジー バイオテクノロジー
- 血液学 ヘマトロジ
- 感染症予防 感染症予防
背景:
- 1970年代から1980年代にかけてのプーリングプラズマの輸血は,HIVとC型肝炎の感染が広まることにつながった.
- この危機は,より安全な凝固因子濃縮物の開発を促した.
- 現在の濃縮物は,病原体伝播に関する優れた安全性記録を持っています.
研究 の 目的:
- 凝固因子濃縮物の進化をレビューする.
- 安全性における進歩と残る治療上の課題を強調する.
- 再結合タンパク質療法における将来の方向性を議論する.
主な方法:
- 輸血関連の感染症に関する過去のデータのレビュー.
- 要素濃縮物の生産における技術的進歩の分析 (ドナーのスクリーニング,ウイルス殺菌技術,再結合DNA技術).
- ヘモフィリア治療における現在のおよび将来の課題の議論.
主要な成果:
- 再結合因子濃縮剤は,血液経由の病原体感染のリスクを大幅に低下させた.
- プリオン伝播リスク,アロ抗体形成,世界的なアクセス格差など,主要な課題は依然として存在しています.
- バイオエンジニアリングによるタンパク質は,薬理学的な性質を向上させ,免疫原性を低下させる可能性を秘めています.
結論:
- 凝固因子濃縮物の安全性については,著しい進展がみられた.
- 残る課題に取り組むことは,包括的な血友病ケアにとって極めて重要です.
- 将来の治療法は,バイオエンジニアリングによる高度な再結合タンパク質を含む可能性が高い.
関連する概念動画
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:06Coagulation
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
01:09EDTA: Conditional Formation Constant
Each EDTA molecule has six binding sites: four carboxyl groups and two amino groups. The fully protonated form of EDTA is represented as H6Y2+. However, it can exist in different forms, H5Y+, H4Y, H3Y−, H2Y2−, and HY3−, depending on the pH of the solution. In very basic solutions with pH > 10.17, the fully deprotonated form, Y4−, is the predominant species that readily complexes with metal ions in a 1:1 ratio.
For the equilibrium reaction of the metal with the Y4− form of EDTA, the formation...
For the equilibrium reaction of the metal with the Y4− form of EDTA, the formation...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:26EDTA: Auxiliary Complexing Reagents
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...